Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
M Elaine HusniAtul A DeodharSergio SchwartzmanSoumya D ChakravartyElizabeth C HsiaJocelyn H LeuYiying ZhouKim H LoArthur KavanaughPublished in: Arthritis research & therapy (2022)
gov , NCT02186873 . Registered on July 10, 2014.